Allen Capital Group’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.27M | Buy |
218,728
+7,145
| +3% | +$187K | 0.43% | 52 |
|
|
2026
Q1 | $5.94M | Buy |
211,583
+15,347
| +8% | +$409K | 0.53% | 47 |
|
|
2025
Q4 | $4.89M | Buy |
196,236
+9,688
| +5% | +$244K | 0.45% | 53 |
|
|
2025
Q3 | $4.75M | Buy |
186,548
+17,363
| +10% | +$429K | 0.45% | 55 |
|
|
2025
Q2 | $4.1M | Buy |
169,185
+26,149
| +18% | +$610K | 0.42% | 58 |
|
|
2025
Q1 | $3.62M | Buy |
143,036
+17,454
| +14% | +$457K | 0.41% | 59 |
|
|
2024
Q4 | $3.33M | Buy |
125,582
+11,661
| +10% | +$316K | 0.4% | 55 |
|
|
2024
Q3 | $3.3M | Buy |
113,921
+9,546
| +9% | +$278K | 0.41% | 55 |
|
|
2024
Q2 | $2.92M | Buy |
104,375
+586
| +0.6% | +$16.1K | 0.4% | 58 |
|
|
2024
Q1 | $2.88M | Sell |
103,789
-3,969
| -4% | -$110K | 0.41% | 55 |
|
|
2023
Q4 | $3.1M | Buy |
107,758
+40,145
| +59% | +$1.21M | 0.49% | 45 |
|
|
2023
Q3 | $2.29M | Buy |
67,613
+2,026
| +3% | +$71.6K | 0.41% | 55 |
|
|
2023
Q2 | $2.41M | Buy |
65,587
+4,164
| +7% | +$162K | 0.41% | 55 |
|
|
2023
Q1 | $2.51M | Buy |
+61,423
| New | +$2.65M | 0.46% | 53 |
|
|
2022
Q4 | – | Sell |
-43,825
| Closed | -$1.92M | – | 120 |
|
|
2022
Q3 | $1.92M | Buy |
43,825
+2,086
| +5% | +$101K | 0.44% | 51 |
|
|
2022
Q2 | $2.19M | Buy |
41,739
+795
| +2% | +$40.5K | 0.44% | 47 |
|
|
2022
Q1 | $2.12M | Buy |
40,944
+1,351
| +3% | +$70.1K | 0.4% | 55 |
|
|
2021
Q4 | $2.34M | Buy |
39,593
+172
| +0.4% | +$8.52K | 0.29% | 63 |
|
|
2021
Q3 | $1.7M | Buy |
39,421
+1,064
| +3% | +$47.1K | 0.34% | 63 |
|
|
2021
Q2 | $1.5M | Buy |
38,357
+9,974
| +35% | +$388K | 0.3% | 66 |
|
|
2021
Q1 | $1.03M | Buy |
28,383
+6,424
| +29% | +$228K | 0.23% | 78 |
|
|
2020
Q4 | $808K | Buy |
21,959
+857
| +4% | +$31.4K | 0.19% | 81 |
|
|
2020
Q3 | $739K | Sell |
21,102
-128
| -0.6% | -$4.49K | 0.19% | 80 |
|
|
2020
Q2 | $659K | Buy |
+21,230
| New | +$721K | 0.17% | 80 |
|
|
2019
Q1 | – | Sell |
-10,766
| Closed | -$434K | – | 122 |
|
|
2018
Q4 | $434K | Buy |
10,766
+3,294
| +44% | +$137K | 0.15% | 89 |
|
|
2018
Q3 | $312K | Buy |
7,472
+930
| +14% | +$35.8K | 0.1% | 104 |
|
|
2018
Q2 | $225K | Sell |
6,542
-2,186
| -25% | -$74.7K | 0.08% | 112 |
|
|
2018
Q1 | $294K | Buy |
+8,728
| New | +$300K | 0.11% | 99 |
|
Other funds holding PFE
Allen Capital Group's PFE Position: Q2 2026 in Review
Allen Capital Group increased its Pfizer (PFE) stake by 3.4% in Q2 2026, buying an estimated $187K and bringing the position to 218,728 shares worth $5.27M. The position accounts for 0.43% of the portfolio, ranked #52.
Allen Capital Group first reported a position in PFE in Q1 2018 and has held it in 28 quarters since. The position peaked at $5.94M in Q1 2026. 2,829 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Allen Capital Group held 218,728 shares of Pfizer worth $5.27M as of Q2 2026.
- Allen Capital Group bought 7,145 Pfizer shares in Q2 2026, an estimated $187K.
- Pfizer made up 0.43% of Allen Capital Group's portfolio in Q2 2026, its #52 holding.
- Allen Capital Group first reported a position in Pfizer in Q1 2018 and has held it in 28 quarters since.
- Allen Capital Group's Pfizer position peaked at $5.94M in Q1 2026.
- 2,829 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Allen Capital Group's 13F filing for Q2 2026, filed 27 Jul 2026.